Next Article in Journal
An Update on 2,5-Diketopiperazines from Marine Organisms
Next Article in Special Issue
The Effects of Omega-3 Fatty Acid on Vitamin D Activation in Hemodialysis Patients: A Pilot Study
Previous Article in Journal
Briarane Diterpenoids from the Gorgonian Dichotella gemmacea
Previous Article in Special Issue
Nano- and Microdelivery Systems for Marine Bioactive Lipids
Article Menu

Export Article

Open AccessReview
Mar. Drugs 2014, 12(12), 6190-6212;

Impact of DHA on Metabolic Diseases from Womb to Tomb

Department of Anatomy, Donders Institute for Brain, Cognition & Behaviour, Radboud University Medical Center, Geert Grooteplein Noord 21, 6525 EZ Nijmegen, The Netherlands
These authors contributed equally to this work.
Author to whom correspondence should be addressed.
Received: 9 October 2014 / Revised: 25 November 2014 / Accepted: 11 December 2014 / Published: 18 December 2014
(This article belongs to the Special Issue Marine Functional Food Products - Cardiovascular Diseases)
Full-Text   |   PDF [637 KB, uploaded 24 February 2015]   |  


Long chain polyunsaturated fatty acids (LC-PUFAs) are important mediators in improving and maintaining human health over the total lifespan. One topic we especially focus on in this review is omega-3 LC-PUFA docosahexaenoic acid (DHA). Adequate DHA levels are essential during neurodevelopment and, in addition, beneficial in cognitive processes throughout life. We review the impact of DHA on societal relevant metabolic diseases such as cardiovascular diseases, obesity, and diabetes mellitus type 2 (T2DM). All of these are risk factors for cognitive decline and dementia in later life. DHA supplementation is associated with a reduced incidence of both stroke and atherosclerosis, lower bodyweight and decreased T2DM prevalence. These findings are discussed in the light of different stages in the human life cycle: childhood, adolescence, adulthood and in later life. From this review, it can be concluded that DHA supplementation is able to inhibit pathologies like obesity and cardiovascular disease. DHA could be a dietary protector against these metabolic diseases during a person’s entire lifespan. However, supplementation of DHA in combination with other dietary factors is also effective. The efficacy of DHA depends on its dose as well as on the duration of supplementation, sex, and age. View Full-Text
Keywords: docosahexaenoic acid; humans; metabolic diseases; cardiovascular disease; obesity; diabetes mellitus type II docosahexaenoic acid; humans; metabolic diseases; cardiovascular disease; obesity; diabetes mellitus type II

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Arnoldussen, I.A.C.; Kiliaan, A.J. Impact of DHA on Metabolic Diseases from Womb to Tomb. Mar. Drugs 2014, 12, 6190-6212.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top